Overall rank by patents
#6,991
Across all tracked assignees
USPTO PatentsView assignee record - 47 granted patents across 3 technology areas, active 2024–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B67D (DISPENSING, DELIVERING OR TRANSFERRING LIQUIDS, NOT OTHERWISE PROVIDED FOR).
The verdict
Botrista holds 47 US patents across 3 technology areas, rank #6,991 of 50,000 tracked assignees.
Botrista, Inc. has been granted 47 US utility patents between 2024 and 2025, placing Botrista, Inc. at rank #6,991 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.4 claims per patent with primary concentration in B67D (DISPENSING, DELIVERING OR TRANSFERRING LIQUIDS, NOT OTHERWISE PROVIDED FOR). As a US Corporation, Botrista, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Botrista sits between B.braun Medical Inc. (47 patents, rank #6,987) and Cleveland Medical Devices Inc. (47 patents, rank #6,995) - the closest US assignees by grant volume. The composite Innovation Score of 44.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2024 through 2025, with 47 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Botrista, Inc.'s 8.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Botrista, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
B.Braun Medical Inc.
47 patents
BEIJING BOE MULTIMEDIA TECHNOLOGY CO., LTD.
47 patents
BI Incorporated
47 patents
BRP-ROTAX GMBH & CO. KG
47 patents
CHUNGHWA PRECISION TEST TECH. CO., LTD.
47 patents
CareView Communications, Inc.
47 patents
Carling Technologies, Inc.
47 patents
Cleveland Medical Devices Inc.
47 patents
Botrista, Inc.
47 patents
What this shows Botrista holds 47 patents at rank #6,991, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,991 in granted patent volume.
Other assignees with the most granted patents in Botrista's primary technology class.
Botrista's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2024 | 17 | 36.2% |
| 2025 | 30 | 63.8% |
Top 3 of 3 technology areas
Overall rank by patents
#6,991
Across all tracked assignees
44.5 out of 100
How to use this portfolio
Botrista's 47 grants land it in the top 25% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.